Search clinical trials for: Liraglutide 3 mg (Saxenda)

Total 714 results

Woman's
Novo Nordisk A/S

Completed

Liraglutide 3mg (Saxenda) on Weight, Body Composition, Hormonal and Metabolic Parameters in Obese Women With PCOS (SAXAPCOS)

Polycystic Ovary Syndrome | Pre Diabetes | Obesity Android

United States
Henrik Gudbergsen

Completed

Biomarkers in Obese Patients With Knee Osteoarthritis; Weight Maintenance (BIO-LOSEIT-II)

Obesity | Osteoarthritis

Denmark
Henrik Gudbergsen

Completed

Multi-parametric Imaging of the Knee in Obese Patients With Knee Osteoarthritis; Weight Maintenance (IM-LOSEIT-II)

Obesity | Osteoarthritis

Denmark
Parker Research Institute

Completed

Changes in Skin Autoflouresence Following Weight Loss and Maintenance Using Liraglutide in Knee Osteoarthritis

Osteoarthritis, Knee

Denmark
Henrik Gudbergsen
Novo Nordisk A/S; Cambridge Weight Plan Limited

Completed

Liraglutide 3 mg for Knee Osteoarthritis (LOSEIT)

Obesity | Osteoarthritis

Denmark
Henrik Gudbergsen

Completed

Ultrasound of the Knee in Obese Patients With Knee Osteoarthritis; Weight Maintenance (US-LOSEIT-II)

Obesity | Osteoarthritis

Denmark
Anders Fink-Jensen, MD, DMSci

Completed

Is Saxenda® a Viable Treatment of Obese Patients in Forensic Psychiatry?

Feasibility | Overweight and Obesity | Metabolic Disturbance | Mental Disorder | Liraglutide

Denmark
Federico II University

Unknown

Effect of Liraglutide on Microbiome in Obesity

Obesity | Weight Loss | Microbiome

Italy
University College, London

Completed

Evaluation of Liraglutide 3.0mg in Patients With Poor Weight-loss and a Suboptimal Glucagon-like Peptide-1 Response (BARIOPTIMISE)

Obesity

United Kingdom
Mayo Clinic
Novo Nordisk A/S

Active, not recruiting

Effect of GLP-1 Receptor Agonism After Sleeve Gastrectomy

Obesity

United States
University of Chicago

Not yet recruiting

Study of Liraglutide (A Weight Loss Drug) in High Risk Obese Participants With Cognitive and Memory Issues

Multiple Sclerosis | Obesity | Obesity, Morbid | Obese | Long COVID | Long Covid19 | Acute Leukemia in Remission
Zuyderland Medisch Centrum
Nederlandse Obesitas Kliniek

Withdrawn

Liraglutide for Low-responders After Bariatric Surgery (LIBAR)

Obesity | Obesity, Morbid
Beth Israel Deaconess Medical Center

Active, not recruiting

Saxenda: Underlying Mechanisms and Clinical Outcomes

Obesity

United States
General Committee of Teaching Hospitals and Institutes...

Not yet recruiting

Effect of Liraglutide on Weight Loss in Patients Who Have Undergone Revisional Bariatric Surgeries.

Morbid Obesity

Egypt
Catholic University of the Sacred Heart

Completed

Weight Loss With Intensive Lifestyle Modifications Plus Bariatric Surgery Versus Liraglutide 3 mg (LETHE)

Obesity

Italy
University of Leicester
Novo Nordisk A/S

Active, not recruiting

Saxenda in Obesity Services (STRIVE Study) (STRIVE)

Obesity | Diabetes Mellitus | Weight Loss

Ireland, United Kingdom
St Vincent's University Hospital, Ireland
University College Dublin; Health Research Board, Ireland

Completed

Effect of Liraglutide vs CPAP on Cardiometabolic Outcomes in Obstructive Sleep Apnea

Sleep Apnea, Obstructive

Ireland
Nicolai Jacob Wewer Albrechtsen
Rigshospitalet, Denmark; Hvidovre University Hospital

Completed

The Effect of Liraglutide on Pancreatic Hormones and Its Size (LIRAP)

Obesity

Denmark
Zoltan Pataky
University of Geneva, Switzerland

Completed

Reward Mechanisms in Obesity (LIRAOB)

Obesity

Switzerland
Beni-Suef University

Not yet recruiting

Effect of Liraglutide in Obese Women With Polycystic Ovary Syndrome

Polycystic Ovary

Egypt
Chinese PLA General Hospital

Unknown

Clinical Study of Liraglutide in Improving Cardiac Function for Patients With Ischemic Cardiomyopathy

Ischemic Cardiomyopathy

China
Lindner Center of HOPE

Completed

Saxenda® in Obese or Overweight Patients With Stable Bipolar Disorder (Investigator Initiated)

Obesity | Bipolar Disorder

United States
Claus Bogh Juhl

Completed

Effects of Liraglutide in Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

Denmark
Texas Tech University
Novo Nordisk A/S

Completed

To Predict Weight Loss Response to Liraglutide (Saxenda®), From fMRI-based Determination of Food Cue Reactivity

Obesity

United States
University of Texas Southwestern Medical Center
Novo Nordisk A/S

Completed

Impact of Liraglutide 3.0 on Body Fat Distribution

Cardiovascular Diseases | Fat Disorder | Obesity, Visceral

United States
Ohio State University

Completed

Improving Beta Cell Function in Mexican American Women With Prediabetes

Pre-Diabetes

United States
Signe Torekov
Karolinska Institutet; University of Oxford; Hvidovre University Hospital

Unknown

Combined Effects of GLP-1 Analogue and Exercise on Maintenance of Weight Loss and Health After Very-low Calorie Diet (S-LITE)

Obesity

Denmark
Mayo Clinic
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Novo...

Completed

Pilot Study of the Effect of Liraglutide on Weight Loss and Gastric Functions in Obesity

Obesity

United States
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Non-diabetic Severely Obese Participants

Obesity

United States, Belgium, United Kingdom, Sweden, Poland, Canada
Amgen

Completed

Multiple Ascending Dose Study of AMG 598 in Adults With Obesity

Obesity

United States
University Hospitals Coventry and Warwickshire...
University of Warwick; University of Birmingham; Kingston University

Unknown

3mg Liraglutide for Overweight or Obesity

Obesity | Overweight | Infertility, Female

United Kingdom
Merck Sharp & Dohme LLC

Completed

Evaluation of the Glucoregulatory Effects of Glucagon-like Peptide-1 Receptor (GLP-1 Receptor) Activation in Participants With Type 2 Diabetes Mellitus (MK-0000-222)

Type 2 Diabetes Mellitus
Novo Nordisk A/S

Completed

A Research Study About Weight Loss and Treatment Patterns With the Use of Saxenda® in Adults in Real-life Settings in Switzerland

Obesity or Overweight

Denmark
Michael Camilleri, MD
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Novo...

Completed

Pilot Study of the Effect of Liraglutide 3.0 mg on Weight Loss and Gastric Functions in Obesity

Obesity

United States
Kelly Allison
Novo Nordisk A/S

Terminated

Binge Eating Liraglutide Intervention (BELIEVE)

Binge-Eating Disorder

United States
Milton S. Hershey Medical Center
National Institute on Drug Abuse (NIDA); National Institutes of Health (NIH)

Completed

Use of a GLP-1R Agonist to Treat Opioid Use Disorder

Opioid-Related Disorders | Opiate Substitution Treatment

United States
Novo Nordisk A/S

Completed

Research Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity.

Obesity | Overweight

United States, United Kingdom, Canada, Denmark, Finland, Serbia, Poland, Japan, South Africa, Ireland
NYU Langone Health
Novo Nordisk A/S

Completed

Clinical Efficacy and Safety of Using 3.0mg Liraglutide to Treat Weight Regain After Roux-en-Y Gastric Bypass Surgery

Obesity

United States
University Health Network, Toronto

Recruiting

Incretin and Treatment With Inhibition of Sodium-glucose Cotransporter-2 Combination Insights Into Mechanisms Implicated in Congestive Heart Failure: "NATRIURETIC" Trial (NATRIURETIC)

Type 2 Diabetes Mellitus

Canada
Rebecca Ashare
Novo Nordisk A/S

Completed

Daily Liraglutide for Nicotine Dependence (DAL)

Smoking Cessation | Weight, Body

United States
Novo Nordisk A/S

Enrolling by invitation

Study to Evaluate the Safety and Effectiveness of Saxenda® for Weight Management in Routine Clinical Practice in Taiwan.

Obesity

Taiwan
Novo Nordisk A/S

Completed

Research Study Comparing Different Tablets With the Study Medicine Semaglutide in Healthy Men

Diabetes Mellitus, Type 2

Germany
Seoul National University Hospital

Recruiting

The Effect of GLP-1 Agonist in Patients With Hypothalamic Obesity: Prospective, Pilot Study

Craniopharyngioma | Panhypopituitarism | Hypothalamic Obesity

Korea, Republic of
Hospital General de México Dr. Eduardo Liceaga

Completed

Serum Insulin Response After Acute and Chronic Sucralose Ingestion in Healthy Volunteers With Variable Body Mass Index

Healthy
Novo Nordisk A/S

Completed

Timely Detection of Treatment Emergent Serious and Non-serious Adverse Events for Saxenda® in Mexican Patients

Obesity

Mexico
Novo Nordisk A/S

Completed

Effect and Safety of Liraglutide 3.0 mg in Subjects With Overweight or Obesity and Type 2 Diabetes Mellitus Treated With Basal Insulin (SCALE™ Insulin)

Obesity | Metabolism and Nutrition Disorder

United States, Israel, Italy, Mexico, Canada, Germany, Turkey
University of Campinas, Brazil

Unknown

Influence of Liraglutide, a GLP-1 Receptor Agonist, on Brown Adipose Tissue (BAT) Activity in Humans (i-LAB)

Obesity | Type 2 Diabetes Mellitus
Cedars-Sinai Medical Center
Novo Nordisk A/S; The Cure Parkinson's Trust

Completed

Safety and Efficacy of Liraglutide in Parkinson's Disease

Parkinson Disease

United States
Turku University Hospital

Active, not recruiting

Liraglutide in the Prevention of Type 2 Diabetes After Gestational Diabetes (Liragest)

Gestational Diabetes

Finland
Autoimmune Technologies, LLC

Completed

Safety Study of Flufirvitide-3 Nasal Spray in Healthy Subjects

Influenza

United States

Search clinical trials for: Liraglutide 3 mg (Saxenda)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in South Africa

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations